NRAS and melanoma: One study identified acquired oncogenic mutations in NRAS and the loss of CDKN2A in BRAF-V600E-mutant melanoma tumors from two patients who progressed on BRAF/MEK inhibitors, suggesting that the reactivation of MAPK and the activation of cell cycle pathways contribute to resistance.